About your Search

20130416
20130424
Search Results 0 to 2 of about 3
-term, but in this environment, where sentiment, we've got unusually bearish quickly. we've got more weakness in store. >> so you would wait. this isn't necessarily an entry point for you, yet? >> no, if i had cash on the sidelines, pretty much at the close of today, the average stock in the s&p 500 was off about 7% from its 52-week high. the average technology stock, 11% from its 52-week high, if we get another 3% to 5% down in stocks, then i think that cash on the sidelines should be absolutely put to work, because the next two or three years still bodes quite well for the stock market relative to most other asset classes. >> i may have to break in momentarily when those american express earnings come out. but first, jerry webben, let me ask you, the fear has been this week with news out of china, some of the economic data that we've gotten here, that maybe the global growth rate is slowing down. do you sense that at all? >> i think, yes, both in the u.s. and in china, we've seen some slowness in the emerging markets and europe remains extremely weak, but you've got to look at those growth areas in the u.s. wi
as the competitive environment, do any of these other competitive services end up adding up to anything? i think so far the answer is clearly no. we're not seeing much from amazon prime or hulu or some of the other services to really grab share from netflix. >> yeah? all right. we will leave it there. thanks, everybody. appreciate your time tonight. see you soon. >> thank you. >> thanks. >> thank you so much. >>> shares of johnson & johnson meanwhile hitting an all-time high today. ceo alex gorsky is up next in an interview you'll only see here. the company's first quarter sales were $17.5 billion. we'll find out what he's got planned for the second quarter right after this break. stay with us. >>> >>> welcome back. johnson & johnson shares at an all-time high. 84.83 tl$84.83 a share. the company enjoyed a major boost after the potential type 2 diabetes drug was granted fda approval. let's check in on j & j. has the brand fully recovered from product recalls? ceo alex gorsky. >> great to see you almost a year later. >> a year later. when you first started, we talked a bit. let me go back to when we
. private equity is certainly doing well in this environment. i'm, i guess, a little surprised that we haven't seen more deals, given the fact that rates are at such low levels. shouldn't we be seeing a whole host of deal flow and deal activity? >> we should, and we may. i guess, the opposite side of a coin of a buoyant stock market is higher evaluations and less attractive targets in the public arena. as a stock holder, and i was glad to see blackstone back off from a bid on dell. but, you know, these companies are kind of out of the mainstream. if you're a stock holder, you're actually a unit holder. you get a k-1 form, as if you were a limited partner in almost a hedge fund. the accounting is eccentric, because, well, because gap doesn't quite do these companies justice. so you have to look at this so-called economic net income. and there's this seeming paradox of private equity companies being in the private market. and if private equities are so great, why are they public? there's a lot of bad will, i think, towards these companies, but they offer that thing that is most scarce today in
Search Results 0 to 2 of about 3

Terms of Use (10 Mar 2001)